ClinicalTrials.gg
CompletedNCT07128212Updated Aug 17, 2025

Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1

An interventional study of Atorvastatin 10 mg daily and Placebo matching atorvastatin in Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease and Vascular Cell Adhesion Molecule-1, sponsored by Suzhou Municipal Hospital of Anhui Province. Completed at 1 site in China. Open to participants aged 45 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Suzhou Municipal Hospital of Anhui Province · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 7 months after the study started (first participant enrolled Jan 2021, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
45 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.

Enrollment
6th of 26
401 · median 105
Started
2021
with 3 others
No phase
16 of 48
9 open now
Registered
40th of 48
by date

Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 with no phase, and was the 40th registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Cerebral Small Vessel Diseases with a site in China, or all of them as a file.
02

Study summary

This prospective study will enroll patients younger than 60 years with ischemic white matter lesions (WMIL) and age-matched healthy controls. We will measure circulating endothelial-related biomarkers, including endothelial progenitor cells (EPCs), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), asymmetric dimethylarginine (ADMA), and homocysteine (Hcy). We will also assess transcription levels of ICAM-1, VCAM-1, and ADMA. All participants will be followed and managed for 2 years, with repeated assessments of endothelial biomarkers and their transcriptional levels, as well as clinical and imaging evaluations. The aims are to characterize changes in endothelial biomarkers in WMIL, to determine how these changes relate to clinical features and imaging progression, and to evaluate whether statins protect endothelial function-by modifying these biomarkers-and thereby help treat WMIL and slow its progression.

03

Conditions studied

  • Ischemic White Matter Lesions (WMIL)
  • Cerebral Small Vessel Disease
  • Vascular Cell Adhesion Molecule-1
  • VCAM-1
04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 45-60 years.
  • Provides written .
  • WMIL group: consecutive outpatients/inpatients from the Neurology Department of Suzhou Municipal Hospital, with WMIL confirmed by brain MRI. Diagnostic features: symmetric, diffusely distributed, ill-defined lesions in periventricular and subcortical white matter; iso- or hypointense on T1WI; hyperintense on T2WI and FLAIR.
  • Control group: healthy individuals aged 45-60 years with brain MRI showing no intracranial lesions.

Exclusion criteria

Exclusion Criteria:

  • Acute intracerebral hemorrhage or acute infarction on brain MRI or CT.
  • Central nervous system diseases that severely affect cognition, such as Alzheimer's disease or frontotemporal dementia.
  • White matter lesions due to other causes (e.g., toxic, genetic, immune, infectious, neoplastic, radiation-related).
  • Severe hepatic, renal, or cardiac insufficiency.
  • Recent major surgery or severe trauma.
  • History of psychiatric disorders that would preclude completion of study scales.
  • Unable to provide written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    WMH - Intervention

    Participants with WMH receiving oral atorvastatin 10 mg once daily at 18:00 (6 p.m.) for 24 months. Standard assessments will be performed at baseline and follow-up.

    Drug: Atorvastatin 10 mg daily

  • Placebo comparator
    WMH - Placebo

    Participants with WMH receiving a placebo tablet matching atorvastatin, administered orally once daily at 18:00 (6 p.m.) for the same duration as the intervention arm. The same assessments will be performed.

    Drug: Placebo matching atorvastatin

  • No intervention
    Health Control

    Health control participants with no study intervention; baseline and follow-up assessments only over the same schedule as patient groups.

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.

    Also known as: Atorvastatin calcium, ATV

  • DrugPlacebo matching atorvastatin

    Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.

06

What researchers measure

Primary outcomes

  1. VACM1 levels at 0.5, 1.0, 1.5, and 2.0 years

    Time frame: 0.5, 1, 1.5, and 2.0 years after baseline

07

Study locations

1 site
  • Suzhou Hospital of Anhui Medical University
    Suzhou, Anhui 234000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2022, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Jan 1, 2021
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07128212
Lead sponsor
Suzhou Municipal Hospital of Anhui Province
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Jan 1, 2021
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Aug 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion